This finding is supported by a study into CD8+ cell responses to the SARS-CoV-2 vaccine in patients with CVID and XLA compared to healthy controls, which showed a greater CD8+ and functional CTL response in XLA compared to controls, but a worse response in CVID compared to controls [91]. Here, CD8A is linked to Bruton-type agammaglobulinemia.